The Characteristics of Transcription Factors Regulating T Cell Exhaustion Were Analyzed to Predict the Prognosis and Therapeutic Effect in Patients with HCC

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. doi:10.1016/j.suronc.2016.03.002
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855. doi:10.1136/gutjnl-2013-306627
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7(1):267. doi:10.1186/s40425-019-0749-z
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88. doi:10.1016/j.jhep.2013.02.022
   PubMed Web of Science ®Google Scholar
• Xu W, Liu K, Chen M, et al. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Ther Adv Med Oncol. 2019;11:1758835919862692. doi:10.1177/1758835919862692
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–2589. doi:10.2217/fon-2020-0669
   PubMed Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361–369. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021;12:783236. doi:10.3389/fimmu.2021.783236
   PubMed Web of Science ®Google Scholar
• Lu C, Rong D, Zhang B, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18(1):130. doi:10.1186/s12943-019-1047-6
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Kucharz J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023;72(6):1365–1379. doi:10.1007/s00262-022-03349-4
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Mollica V, et al. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596. doi:10.1016/j.critrevonc.2022.103596
   PubMed Web of Science ®Google Scholar
• Zhao M, Huang H, He F, Fu X. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma. Front Immunol. 2023;14:1188277. doi:10.3389/fimmu.2023.1188277
   PubMedGoogle Scholar
• Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396. doi:10.1186/s13046-019-1396-4
   PubMed Web of Science ®Google Scholar
• Mohr R, Jost-Brinkmann F, Özdirik B, et al. Lessons from immune checkpoint inhibitor trials in hepatocellular carcinoma. Front Immunol. 2021;12:652172. doi:10.3389/fimmu.2021.652172
   PubMed Web of Science ®Google Scholar
• Kotsari M, Dimopoulou V, Koskinas J, Armakolas A. Immune system and Hepatocellular Carcinoma (HCC): new insights into HCC progression. Int J Mol Sci. 2023;24(14):11471. doi:10.3390/ijms241411471
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kamphorst AO, Im SJ, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69(1):301–318. doi:10.1146/annurev-med-012017-043208
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862
   PubMed Web of Science ®Google Scholar
• McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37(1):457–495. doi:10.1146/annurev-immunol-041015-055318
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670–684. doi:10.1016/j.immuni.2007.09.006
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–1356.e16. doi:10.1016/j.cell.2017.05.035
   PubMed Web of Science ®Google Scholar
• Kuang T, Zhang L, Chai D, Chen C, Wang W. Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma. Aging. 2023;15(12):5751–5774. doi:10.18632/aging.204830
   PubMedGoogle Scholar
• Shi J, Li G, Liu L, et al. Establishment and validation of exhausted CD8+ T cell feature as a prognostic model of HCC. Front Immunol. 2023;14:1166052. doi:10.3389/fimmu.2023.1166052
   PubMed Web of Science ®Google Scholar
• Nayar R, Schutten E, Bautista B, et al. Graded levels of IRF4 regulate CD8+ T cell differentiation and expansion, but not attrition, in response to acute virus infection. J Immunol. 2014;192(12):5881–5893. doi:10.4049/jimmunol.1303187
   PubMed Web of Science ®Google Scholar
• Porter CM, Clipstone NA. Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD4+ T cells. J Immunol. 2002;168(10):4936–4945. doi:10.4049/jimmunol.168.10.4936
   PubMed Web of Science ®Google Scholar
• Scott AC, Dündar F, Zumbo P, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270–274. doi:10.1038/s41586-019-1324-y
   PubMed Web of Science ®Google Scholar
• Man K, Gabriel SS, Liao Y, et al. Transcription factor IRF4 promotes CD8+ T cell exhaustion and limits the development of memory-like T cells during chronic infection. Immunity. 2017;47(6):1129–1141.e5. doi:10.1016/j.immuni.2017.11.021
   PubMed Web of Science ®Google Scholar
• Martinez GJ, Pereira RM, Äijö T, et al. The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells. Immunity. 2015;42(2):265–278. doi:10.1016/j.immuni.2015.01.006
   PubMed Web of Science ®Google Scholar
• Seo H, González-Avalos E, Zhang W, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol. 2021;22(8):983–995. doi:10.1038/s41590-021-00964-8
   PubMed Web of Science ®Google Scholar
• Seo H, Chen J, González-Avalos E, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci U S A. 2019;116(25):12410–12415. doi:10.1073/pnas.1905675116
   PubMed Web of Science ®Google Scholar
• McLane LM, Ngiow SF, Chen Z, et al. Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Rep. 2021;35(6):109120. doi:10.1016/j.celrep.2021.109120
   PubMed Web of Science ®Google Scholar
• Alfei F, Kanev K, Hofmann M, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019;571(7764):265–269. doi:10.1038/s41586-019-1326-9
   PubMed Web of Science ®Google Scholar
• Yuan K, Zhao S, Ye B, et al. A novel T-cell exhaustion-related feature can accurately predict the prognosis of OC patients. Front Pharmacol. 2023;14:1192777. doi:10.3389/fphar.2023.1192777
   PubMed Web of Science ®Google Scholar
• Chen L, Lin YH, Liu GQ, et al. Clinical significance and potential role of LSM4 overexpression in hepatocellular carcinoma: an integrated analysis based on multiple databases. Front Genet. 2022;12:804916. doi:10.3389/fgene.2021.804916
   PubMed Web of Science ®Google Scholar
• Chen L, Yang Z, Cao Y, et al. Pan-cancer analysis and single-cell analysis revealed the role of ABCC5 transporter in hepatocellular carcinoma. Channels. 2021;15(1):541–554. doi:10.1080/19336950.2021.1968592
   PubMed Web of Science ®Google Scholar
• Zhang R, Xia Y, Dong J, et al. Comprehensive analysis of m7G-related genes and chronic hepatitis B: diagnostic markers, immune microenvironment regulation, disease progression. J Immunol Res. 2023;2023:9471520. doi:10.1155/2023/9471520
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–112. doi:10.1038/nature08460
   PubMed Web of Science ®Google Scholar
• Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2(10):1001–1012. doi:10.1038/s42255-020-00280-9
   PubMedGoogle Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45–56. doi:10.1038/nri3790
   PubMed Web of Science ®Google Scholar
• Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17(1):53. doi:10.1186/s12874-017-0332-6
   PubMed Web of Science ®Google Scholar
• Abd ElHafeez S, Torino C, D’Arrigo G, et al. An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan-Meier analysis and the Cox regression method. Aging Clin Exp Res. 2012;24(3):203–206. doi:10.1007/BF03325249
   PubMed Web of Science ®Google Scholar
• Dong J, Zhang R, Xia Y, et al. The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC. Front Immunol. 2023;14:1142319. doi:10.3389/fimmu.2023.1142319
   PubMed Web of Science ®Google Scholar
• Zhong Z, Xie F, Yin J, et al. Development of a prognostic model for anoikis and identifies hub genes in hepatocellular carcinoma. Sci Rep. 2023;13(1):14723. doi:10.1038/s41598-023-41139-9
   PubMed Web of Science ®Google Scholar
• Wanderley CW, Colón DF, Luiz JPM, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res. 2018;78(20):5891–5900. doi:10.1158/0008-5472.CAN-17-3480
   PubMed Web of Science ®Google Scholar
• Zong Z, Zou J, Mao R, et al. M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1β signaling. Front Immunol. 2019;10:1643. doi:10.3389/fimmu.2019.01643
   PubMed Web of Science ®Google Scholar
• Sanjurjo L, Aran G, Roher N, Valledor AF, Sarrias MR. AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease. J Leukoc Biol. 2015;98(2):173–184. doi:10.1189/jlb.3RU0215-074R
   PubMed Web of Science ®Google Scholar
• Bárcena C, Aran G, Perea L, et al. CD5L is a pleiotropic player in liver fibrosis controlling damage, fibrosis and immune cell content. EBioMedicine. 2019;43:513–524. doi:10.1016/j.ebiom.2019.04.052
   PubMed Web of Science ®Google Scholar
• Sanchez-Moral L, Paul T, Martori C, et al. Macrophage CD5L is a target for cancer immunotherapy. EBioMedicine. 2023;91:104555. doi:10.1016/j.ebiom.2023.104555
   PubMed Web of Science ®Google Scholar
• Barnum SR, Bubeck D, Schein TN. Soluble membrane attack complex: biochemistry and immunobiology. Front Immunol. 2020;11:585108. doi:10.3389/fimmu.2020.585108
   PubMed Web of Science ®Google Scholar
• Barroso S, López-Trascasa M, Merino D, Alvarez AJ, Núñez-Roldán A, Sánchez B. C7 deficiency and meningococcal infection susceptibility in two spanish families. Scand J Immunol. 2010;72(1):38–43. doi:10.1111/j.1365-3083.2010.02403.x
   PubMed Web of Science ®Google Scholar
• Chen Z, Yan X, Du GW, et al. Complement C7 (C7), a potential tumor suppressor, is an immune-related prognostic biomarker in Prostate Cancer (PC). Front Oncol. 2020;10:1532. doi:10.3389/fonc.2020.01532
   PubMed Web of Science ®Google Scholar
• Ying L, Zhang F, Pan X, et al. Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis. Oncotarget. 2016;7(52):86536–86546. doi:10.18632/oncotarget.13294
   PubMedGoogle Scholar
• Seol HS, Lee SE, Song JS, et al. Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. Cancer Lett. 2016;372(1):24–35. doi:10.1016/j.canlet.2015.12.005
   PubMed Web of Science ®Google Scholar
• Szaflik JP, Majsterek I, Kowalski M, et al. Association between sorbitol dehydrogenase gene polymorphisms and type 2 diabetic retinopathy. Exp Eye Res. 2008;86(4):647–655. doi:10.1016/j.exer.2008.01.009
   PubMed Web of Science ®Google Scholar